Investment Rating - The report maintains a "Buy" rating for the company, expecting a relative price increase of over 20% compared to the benchmark index within the next 6 to 12 months [12]. Core Insights - The company reported a revenue of 46.12 billion yuan for 2024, a year-on-year increase of 11%, and a net profit attributable to shareholders of 8.01 billion yuan, up 6% [4][5]. - In Q1 2025, the company achieved a revenue of 10.74 billion yuan, reflecting a 35% year-on-year growth, with a net profit of 1.70 billion yuan, up 54% [4][5]. - The demand for superconducting products and titanium alloys continues to grow, contributing to steady revenue growth in 2024 [5]. - The gross profit margin improved to 33.55% in 2024, an increase of 1.68 percentage points year-on-year, with effective cost control across various expense categories [6]. - The company has established a significant supply advantage in superconducting products, benefiting from increased demand in medical, controlled nuclear fusion, and other sectors [7]. - The titanium alloy products maintain a dominant market position in the aerospace sector, with successful applications in helicopters, drones, and commercial aircraft [8]. - The company expects net profits attributable to shareholders to reach 10.07 billion, 12.30 billion, and 14.27 billion yuan for 2025, 2026, and 2027, respectively, corresponding to price-to-earnings ratios of 32, 26, and 22 times [6][10]. Financial Summary - For 2024, the company reported total revenue of 46.12 billion yuan, with a projected revenue increase to 54.49 billion yuan in 2025, representing a growth rate of 18.14% [10]. - The net profit attributable to shareholders is expected to grow from 8.01 billion yuan in 2024 to 10.07 billion yuan in 2025, reflecting a growth rate of 25.70% [10]. - The company's earnings per share (EPS) is projected to increase from 1.23 yuan in 2024 to 1.55 yuan in 2025 [10].

富创精密（ [Table_StockNameRptType] 688409） | 近 12 个月最高/最低（元） | 78.00/31.14 | | --- | --- | | 总股本（百万股） | 306 | | 流通股本（百万股） | 177 | | 流通股比例（%） | 57.87 | | 总市值（亿元） | 151 | | 流通市值（亿元） | 87 | [ 公司价格与沪深 Table_Chart] 300 走势比较 -37% -7% 23% 52% 82% 5/24 8/24 11/24 2/25 富创精密 沪深300 [Table_Author] 分析师：陈耀波 | 执业证书号：S0010523060001 | | --- | | 邮箱： chenyaobo@hazq.com | 分析师：李美贤 公司点评 战略投入期，积极扩张国内外产能 | 投资评级：增持（维持） [Table_Rank] | | --- | | 报告日期： 2025-05-15 | | [Table_BaseData] 收盘价（元） 49.31 | 受新产线折旧摊销增加、战略性扩招、关键技术攻关等多项战略举措的 影响，公司 Q1 ...

证券研究报告：国防军工 | 公司点评报告 发布时间：2025-05-15 股票投资评级 增持|维持 个股表现 -42% -33% -24% -15% -6% 3% 12% 21% 30% 39% 48% 2024-08 2024-10 2024-12 2025-01 2025-03 2025-05 佳力奇 国防军工 资料来源：聚源，中邮证券研究所 公司基本情况 | 最新收盘价（元） | 53.36 | | --- | --- | | 总股本/流通股本（亿股）0.83 / 0.21 | | | 总市值/流通市值（亿元）44 / 11 | | | 52 周内最高/最低价 | 73.40 / 36.01 | | 资产负债率(%) | 20.6% | | 市盈率 | 36.80 | | 第一大股东 | 路强 | 研究所 分析师:鲍学博 SAC 登记编号:S1340523020002 Email:baoxuebo@cnpsec.com 分析师:马强 SAC 登记编号:S1340523080002 Email:maqiang@cnpsec.com 佳力奇(301586) 交付能力显著提升，多方向开拓市场成长空间广阔 ⚫ ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is expected to gradually stabilize and improve its performance as it deepens its advantages in key regions [1] - The report highlights that the company's revenue and profit have been under pressure due to various factors, including losses from new stores and increased depreciation [4][5] - The company is focusing on expanding its retail business and enhancing its new retail ecosystem, with significant growth in online sales and O2O services [4][5] Summary by Sections Financial Performance - In 2024, the company achieved total revenue of 22.36 billion yuan (down 0.36% year-on-year) and a net profit of 519 million yuan (down 44.13% year-on-year) [4][5] - For Q1 2025, the company reported revenue of 5.43 billion yuan (down 1.88% year-on-year) and a net profit of 251 million yuan (down 21.98% year-on-year) [4][5] - The company’s gross margin for 2024 was 33.17%, with a net margin of 3.06% [4][5] Business Segments - Retail business revenue was 19.11 billion yuan (down 1.25% year-on-year), while franchise, alliance, and distribution revenue was 3.11 billion yuan (up 5.92% year-on-year) [4] - The company has been expanding its product line in the new retail sector, with online sales reaching approximately 2.47 billion yuan in 2024, a growth of about 24% [4] Market Strategy - The company plans to continue focusing on its advantageous markets and accelerate its presence in lower-tier cities, with 80% of new stores in 2024 located in cities at or below the prefecture level [4][5] - The total number of stores reached 15,277 by the end of 2024, with a net increase of 1,703 stores, reflecting a year-on-year growth of 12.55% [4][5] Profit Forecast - The company’s net profit forecasts for 2025, 2026, and 2027 are 692 million yuan, 799 million yuan, and 909 million yuan, respectively [5] - The expected EPS for the same years is 0.91 yuan, 1.05 yuan, and 1.20 yuan [5]

研究所： 证券分析师： 杨仁文 S0350521120001 yangrw@ghzq.com.cn 证券分析师： 方博云 S0350521120002 fangby@ghzq.com.cn 2025 年 05 月 15 日 公司研究 评级：买入(维持) [Table_Title] 现金投资+战略合作 52TOYS，强化 IP 衍生品业 务布局 ——万达电影（002739）公司点评 最近一年走势 | 相对沪深 | 300 | 表现 | 2025/05/15 | | | --- | --- | --- | --- | --- | | 表现 | | 1M | 3M | 12M | | 万达电影 | | -6.0% | -19.8% | -22.2% | | 沪深 300 | | 3.9% | -0.8% | 7.8% | | 市场数据 | 2025/05/15 | | --- | --- | | 当前价格（元） | 10.64 | | 52 周价格区间（元） | 8.90-14.25 | | 总市值（百万） | 22,469.33 | | 流通市值（百万） | 22,188.50 | | 总股本（万股） | 211 ...

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company has a strong foothold in the hemorrhoid treatment market, with a stable patient base and significant growth potential due to the high prevalence of hemorrhoid diseases, which affects over 50% of the population. The overall annual growth rate for hemorrhoid medications is around 7% [7] - The company is expanding its product line into health and wellness sectors, particularly with eye creams and wet wipes, which are gaining traction in the market. The wet wipes segment is experiencing rapid growth, and the company holds competitive advantages in brand and product quality [8] - The company has implemented channel optimization strategies to enhance operational capabilities, focusing on expanding into county-level and lower-tier markets [8] Summary by Sections 1. Hemorrhoid Treatment Market Leadership - The company has over 400 years of history and a unique "Eight Treasure" formula that is recognized as a national intangible cultural heritage, providing a strong efficacy foundation for its products [11] - The company’s product portfolio includes a comprehensive range of hemorrhoid treatments, with a significant market share of 50% in retail sales [7][18] - The company’s pharmaceutical segment contributes 90% of its gross profit, indicating a robust revenue model [39] 2. Growth Potential in Health and Wellness - The company has launched products like the "Little Blue Wet Wipes," which have quickly gained popularity, ranking high on sales charts [28] - The health and wellness segment is expected to enhance brand recognition, especially among younger consumers, thereby increasing the penetration of OTC products [25] 3. Revenue and Profitability Forecast - Projected revenues for 2025-2027 are estimated at 4.346 billion, 5.025 billion, and 5.822 billion yuan, respectively, with net profits expected to be 624 million, 742 million, and 890 million yuan, corresponding to PE ratios of 18.59, 15.64, and 13.04 times [8]

Investment Rating - The investment rating for the company is downgraded to "Accumulate" [7] Core Views - The company's 2024 performance is under short-term pressure, with a revenue of 3.388 billion yuan, a year-on-year increase of 6.18%, and a net profit attributable to shareholders of -970 million yuan [1] - The semiconductor market is recovering slower than expected, impacting the company's performance, particularly due to high inventory levels in the global semiconductor industry [2] - The company is expanding its 300mm silicon wafer production capacity, which is expected to support future growth despite current challenges [3][4] Financial Performance Summary - In 2024, the company reported a revenue of 3.388 billion yuan, with a net profit attributable to shareholders of -970 million yuan, and a net profit after deducting non-recurring items of -1.243 billion yuan [1] - For Q1 2025, the company achieved a revenue of 802 million yuan, a year-on-year increase of 10.60%, but still reported a net loss of -209 million yuan [1] - The average selling price of products has decreased, particularly for 200mm wafers, which has significantly impacted profitability [2] Capacity Expansion and Development - The company has completed the construction of a new 300mm silicon wafer production capacity of 300,000 pieces per month, with total capacity reaching 650,000 pieces per month [3] - The company is also advancing its 300mm ultra-low oxygen and high-resistance silicon wafer technologies, which are being applied in various fields such as renewable energy and RF [3] - The subsidiary Okmetic is expanding its 200mm silicon wafer production, with plans to start operations in Q2 2025 [4] Research and Development - The company increased its R&D expenditure to 266.82 million yuan in 2024, accounting for 7.88% of revenue, with a focus on various market applications including electric vehicles and RF [5] - The company applied for 130 invention patents in 2024, with 24 granted, and has a total of 630 invention patents and 108 utility model patents as of the end of 2024 [5] Investment Recommendations - Due to the slower-than-expected recovery in the global semiconductor industry and the overall decline in silicon wafer shipments, the company's profit forecasts for 2025 and 2026 have been revised downwards [5] - The expected net profit for 2025 is adjusted from 304 million yuan to 23 million yuan, and for 2026 from 416 million yuan to 114 million yuan [5]

Investment Rating - The investment rating for the company is "Buy" and is maintained [6]. Core Views - The company's self-owned brand development has entered a high-speed growth phase, focusing on the "main food" strategy with frequent new product launches, significantly enhancing profitability. The company is expected to launch 2-3 core products in 2025, focusing on upgrading major products and continuously iterating on staple canned food and baked goods. The overseas production capacity is steadily expanding, with a solid global production layout enhancing risk resistance. The profitability of the US and Canadian factories is strong, and the self-owned brand's overseas business is growing rapidly, opening up future performance growth points. The expected EPS for 2025 and 2026 is 1.49 and 1.95 yuan, respectively, corresponding to PE ratios of 38X and 29X, making it a key recommendation [2][4][8]. Summary by Sections Financial Performance - In 2024, the company achieved a revenue of 4.465 billion yuan, a year-on-year increase of 19.15%, and a net profit attributable to shareholders of 394 million yuan, a year-on-year increase of 68.89%. In Q4 of 2024, revenue was 1.276 billion yuan, up 23.31% year-on-year, with a net profit of 112 million yuan, up 98.2% year-on-year. In Q1 of 2025, revenue reached 1.101 billion yuan, a year-on-year increase of 25.41%, with a net profit of 91 million yuan, up 62.13% year-on-year [4][8]. Strategic Insights - The company is focusing on the rapid growth of its self-owned brands, with domestic sales expected to grow by over 40% year-on-year, driven by the rapid growth of the "Wanpi" brand. The company is also expanding its overseas production capacity, with a global strategy taking shape across five countries, including China, the US, Canada, New Zealand, and Cambodia. The US and Canadian factories are expected to add significant snack production capacity, ensuring stable growth and enhancing global supply chain resilience [2][8]. Future Projections - The company is projected to achieve total revenue of 5.124 billion yuan in 2025, with a net profit of 549 million yuan, and further growth is expected in subsequent years, with revenues reaching 6.700 billion yuan and net profits of 714 million yuan by 2026 [14].

Investment Rating - The investment rating for the company is "Buy" and is maintained [6] Core Views - The company set a target for 2024 feed sales growth of 3 million tons, representing a year-on-year increase of 12%. In the first quarter, the year-on-year growth exceeded 25%, surpassing the planned growth rate. The company's performance in the first quarter was better than expected, aided by profits from pig futures hedging. The price of aquatic products is expected to recover by the end of 2024, and the overall price trend in 2025 remains strong, which will drive domestic aquatic feed growth. The long-term potential for feed exports is significant, supporting the company's main business performance growth. The projected main business performance for 2025 and 2026 is 3.85 billion and 4.6 billion yuan, respectively, with a valuation of 10 billion yuan for the breeding business, corresponding to current main business valuations of 21X and 18X, respectively, and the company is continuously recommended [2][4][9] Summary by Sections Financial Performance - In 2024, the company achieved revenue of 114.6 billion yuan, a year-on-year decrease of 1.3%, and a net profit attributable to shareholders of 4.5 billion yuan, a year-on-year increase of 64.3%. In the first quarter of 2025, the company achieved revenue of 25.63 billion yuan, a year-on-year increase of 10.6%, and a net profit attributable to shareholders of 1.28 billion yuan, a year-on-year increase of 49.0% [4][9] Feed Segment - The company plans to sell 24.42 million tons of feed in 2024, a year-on-year increase of 8%, with poultry feed, pig feed, and aquatic feed growing by 12%, -3%, and 11%, respectively. In the first quarter of 2025, feed sales reached 5.95 million tons, a year-on-year increase of 25%, with poultry feed, pig feed, and aquatic feed growing by 20%, 35%, and 20%, respectively. The overseas sales volume increased by 40% year-on-year [9] Breeding Business - The company plans to sell 6 million pigs in 2024, contributing 1.4 to 1.5 billion yuan to performance. In the first quarter of 2025, approximately 1.6 million pigs were sold, with the self-breeding cost reduced to around 13 yuan per kilogram, contributing about 600 million yuan to profits [9] Aquaculture and Seedling Business - The aquaculture segment is expected to recover due to the rebound in fish prices by the end of 2024, and the company has actively reduced production to minimize losses. The seedling business faced delays in stocking due to adverse weather, with profits remaining stable in the first quarter of 2025 [9]

丨证券研究报告丨 [Table_Summary] 2025 年第一季度公司实现营业收入 62.32 亿元，同比增长 25.82%，实现归母净利润 6.05 亿 元，同比增长 25.12%，实现扣非归母净利润 5.93 亿元，同比增长 31.57%。 分析师及联系人 [Table_Author] 陈亮 蔡方羿 高伊楠 SAC：S0490517070017 SAC：S0490516060001 SAC：S0490517060001 SFC：BUW408 SFC：BUV463 SFC：BUW101 联合研究丨公司点评丨爱玛科技（603529.SH） [Table_Title] 产品结构优化，盈利能力稳步提升 报告要点 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com 1 爱玛科技（603529.SH） cjzqdt11111 [Table_Title2] 产品结构优化，盈利能力稳步提升 [Table_Summary2] 事件描述 公司披露一季报：2025 年第一季度公司实现营业收入 62.32 亿元，同比增长 25.82%，实现归 母净利润 6.05 亿元，同比增长 25. ...